Pacifico Biolabs Secures €7M for Mycelium Protein Production

Pacifico Biolabs, a mycelium fermentation protein company, has successfully raised €7 million in a Series A funding round. This investment, as reported by Tech.eu, is earmarked for transforming existing brewery infrastructure into facilities for sustainable protein production. The approach leverages mycelium fermentation, a biotechnological process that offers an alternative to traditional protein sources, aligning with broader trends in sustainable agriculture and the circular economy.

The funding round saw participation from several investors, including Stray Dog Capital, TGFS, Sprout & About Ventures, Simon Capital, and FoodLabs. This significant capital injection underscores continued investor interest in innovative solutions for global food security and environmental sustainability. By repurposing existing industrial sites, Pacifico Biolabs aims to scale its production efficiently, contributing to the development of novel foodtech innovations and alternative proteins.

Investment activity in the broader European technology landscape remains dynamic across diverse sectors. For instance, Certo recently secured $4 million in seed funding for its AI-powered compliance platform, which serves the beauty and consumer goods industries. This capital is intended to accelerate product development and support the company's international expansion, addressing the complex regulatory needs of consumer goods manufacturers. Concurrently, in the property technology sector, InRento has surpassed €100 million in financing, indicating a growing trend among European property developers to explore alternative financing models beyond traditional banking channels.

What this means: The sustained flow of venture capital into areas such as sustainable food technology, AI-driven compliance, and alternative property financing models indicates a clear market appetite for innovative solutions that tackle pressing industry needs, from environmental sustainability and food production to regulatory complexity and accessible investment.